Literature DB >> 32618367

Glycolysis, via NADH-dependent dimerisation of CtBPs, regulates hypoxia-induced expression of CAIX and stem-like breast cancer cell survival.

Mira Kreuzer1,2, Arindam Banerjee1, Charles N Birts1,2, Matthew Darley1, Ali Tavassoli2,3, Mircea Ivan4, Jeremy P Blaydes1,2.   

Abstract

Adaptive responses to hypoxia are mediated by the hypoxia-inducible factor (HIF) family of transcription factors. These responses include the upregulation of glycolysis to maintain ATP production. This also generates acidic metabolites, which require HIF-induced carbonic anhydrase IX (CAIX) for their neutralisation. C-terminal binding proteins (CtBPs) are coregulators of gene transcription and couple glycolysis with gene transcription due to their regulation by the glycolytic coenzyme NADH. Here, we find that experimental manipulation of glycolysis and CtBP function in breast cancer cells through multiple complementary approaches supports a hypothesis whereby the expression of known HIF-inducible genes, and CAIX in particular, adapts to available glucose in the microenvironment through a mechanism involving CtBPs. This novel pathway promotes the survival of stem cell-like cancer (SCLC) cells in hypoxia.
© 2020 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

Entities:  

Keywords:  NADH; breast cancer; carbonic anhydrase IX; glycolysis; hypoxia; stem cell-like cancer cells

Mesh:

Substances:

Year:  2020        PMID: 32618367     DOI: 10.1002/1873-3468.13874

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  1 in total

Review 1.  Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase.

Authors:  Alessio Nocentini; Andrea Angeli; Fabrizio Carta; Jean-Yves Winum; Raivis Zalubovskis; Simone Carradori; Clemente Capasso; William A Donald; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.